.ALPHA.-D-GLUCOSYL-N-ACYLSPHINGOSINE GLUCOHYDROLASE
Gaucher Disease Type I
Sanofiprotein_peptidePhase 4 / ApprovedActive
A
83/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 75/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Gaucher Disease Type I cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Velaglucerase Alfa Baylor Research Institute | Phase 4 | BB |
Miglustat Actelion | Phase 3 | BB |
flt201 Spur Therapeutics | Phase 3 | B |
Acetylcysteine University of Minnesota | Phase 2 | B |
Eliglustat Genzyme, a Sanofi Company | Phase 2 | B |
View all 10 →
Same molecule, other indications
.ALPHA.-D-GLUCOSYL-N-ACYLSPHINGOSINE GLUCOHYDROLASE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →